Arrevus Inc. (www.arrevus.com), an early stage biotechnology company focused on developing chaperone protein inhibitors for infectious diseases, today announced receipt of a $1.5 million Fast-Track grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH), to expedite research on the effects of ARV-1502 on bacteremia caused by "high priority" multi-drug resistant (MDR) pathogens.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,